Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

SEATTLE, May 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 07, 2020 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
May 07, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs

SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
April 27, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study

SEATTLE, April 27, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
April 20, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study

SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19...
April 16, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program

SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
April 02, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Clinical Progress

SEATTLE, April 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast...
March 26, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

SEATTLE, March 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast...
March 13, 2020 08:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Upcoming Meeting with FDA

SEATTLE, March 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer...
March 02, 2020 08:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

SEATTLE, March 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer...